Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (591)	2/18/1999 9:42:00 PM
From: Mike McFarland	Read Replies (1) \| Respond to of 1073

off topic/neuregulins heheh, well if you say that you don't know enough about the subject to judge...than all I most certainly will be able to do is embarrass myself. All I know is what I read...and apparently gram quantities of rhGGF2 were already available for studies as of last fall. The study with Albert Einstein College is in August '98 Proc. Natl. Academy of Science--what triggered my thought to post was rhGGF2 has been shown to actually help regenerate crushed nerves (why not repair the nerve first...worry about synaptic response later). But that was not the paper...the paper was animal model of MS and some success. Ah, I have said too much. I think that is the third time I've posted to your thread on CNSI and remyelination was the topic...not what stock I happen to own. But thanks for enduring it all!